Key result
Robotic magnetic navigation-guided catheter ablation achieves ~89% acute success in CHD patients.
Why the study?
Robotic magnetic navigation has emerged as a potential solution to catheter ablation challenges for arrhythmias in patients with congenital heart disease, but its safety and efficacy required assessment.
Is robotic magnetic navigation-guided catheter ablation safe and effective for treating arrhythmias in patients with congenital heart disease?
Systematic Review (n=167)
Is robotic magnetic navigation-guided catheter ablation safe and effective for treating arrhythmias in patients with congenital heart disease?
RMN-guided catheter ablation is a safe and effective approach for treating arrhythmias in patients with congenital heart disease, achieving high acute success and low recurrence rates.
Answers are grounded in this paper and cite their sources.
Supports robotic magnetic navigation for ablation in CHD; extends Level 1 evidence for complex arrhythmia management.
BACKGROUND: Robotic magnetic navigation (RMN) has emerged as a potential solution to overcome challenges associated with catheter ablation of arrhythmias in patients with congenital heart disease (CHD). OBJECTIVES: To assess safety and efficacy of RMNguided catheter ablation in patients with CHD. DESIGN AND METHODS: A systematic review and pooled analysis was conducted on patients with CHD who underwent RMNguided catheter ablation. Random effects models were used to generate pooled estimates with the inverse variance method used for weighting studies. RESULTS: Twentyfour nonoverlapping records included 167 patients with CHD, mean age 36.5 years, 44.6% female. Type of CHD was simple in 27 (16.2%), moderate in 32 (19.2%), and complex in 106 (63.5%). A total of 202 procedures targeted 260 arrhythmias, the most common being macroreentrant atrial circuits. The mean procedural duration was 207.5 minutes, with a mean fluoroscopy time of 12.1 minutes. The pooled acute success rate was 89.2% [95% CI (77.8%, 97.4%)]. Freedom from arrhythmia recurrence was 84.5% [95% CI (72.5%, 94.0%)] over a mean follow-up of 24.3 months. The procedural complication rate was 3.5% with no complication attributable to RMN technology. CONCLUSION: RMN-guided ablation appears to be safe and effective across a variety of arrhythmia substrates and types of CHD.
No takes yet. Share an insight, caveat, or question.
Vô et al. (2023) conducted a systematic review in congenital heart disease (n=167). Robotic magnetic navigation-guided catheter ablation was evaluated on acute success rate (95% CI 77.8-97.4). Robotic magnetic navigation-guided catheter ablation achieved a pooled acute success rate of 89.2% (95% CI 77.8-97.4%) and 84.5% freedom from recurrence over 24.3 months in patients with CHD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: